Compounds > 1-hydroxy-5,5-dimethyl-2-phenyltetrahydro-4H-imidazole-4-thione
Page last updated: 2024-12-09
1-hydroxy-5,5-dimethyl-2-phenyltetrahydro-4H-imidazole-4-thione
1-hydroxy-5,5-dimethyl-2-phenyltetrahydro-4H-imidazole-4-thione, also known as **PHIT**, is a synthetic compound that has shown promise as a potential therapeutic agent in several areas of research.
**Here's why it's important:**
* **Anti-inflammatory and analgesic activity:** PHIT has demonstrated anti-inflammatory effects in various animal models, including models of arthritis and inflammatory bowel disease. It also possesses analgesic properties, potentially reducing pain associated with inflammation.
* **Neuroprotective effects:** PHIT has been shown to protect neurons from damage caused by oxidative stress, excitotoxicity, and other harmful stimuli. This makes it a potential candidate for treating neurodegenerative diseases like Alzheimer's and Parkinson's.
* **Antioxidant activity:** PHIT is a potent antioxidant, scavenging free radicals and protecting cells from damage caused by oxidative stress.
* **Cancer research:** Preliminary research suggests that PHIT may have anti-cancer properties, potentially inhibiting the growth and spread of certain types of cancer cells.
* **Cardiovascular health:** PHIT has been shown to improve cardiovascular function in animal models, potentially lowering blood pressure and reducing the risk of heart disease.
**Mechanism of action:**
The exact mechanisms by which PHIT exerts its various effects are still being investigated, but some of the proposed mechanisms include:
* **Inhibition of inflammatory mediators:** PHIT can block the production of pro-inflammatory cytokines like TNF-α and IL-1β.
* **Activation of antioxidant pathways:** PHIT may activate antioxidant enzymes like glutathione peroxidase, which help protect cells from oxidative damage.
* **Regulation of cell signaling:** PHIT can influence various signaling pathways involved in inflammation, cell survival, and other processes.
**Current research:**
While PHIT shows promise in preclinical studies, it's still in the early stages of development. Further research is needed to understand its long-term safety and efficacy, as well as to determine its potential for clinical application.
**It's important to note:**
* PHIT is not currently available as a medication.
* Further research is necessary to confirm its therapeutic potential and safety in humans.
Overall, 1-hydroxy-5,5-dimethyl-2-phenyltetrahydro-4H-imidazole-4-thione (PHIT) is a promising compound with potential applications in a wide range of medical fields. Its anti-inflammatory, neuroprotective, and antioxidant properties make it an exciting area of research for developing new treatments for various diseases.
Cross-References
Synonyms (21)
Synonym |
IDI1_031044 |
SR-01000212856-2 |
MAYBRIDGE4_000462 |
NCGC00177554-01 |
HMS1522E22 |
BRD-A65358252-001-01-4 |
1-hydroxy-5,5-dimethyl-2-phenyltetrahydro-4h-imidazole-4-thione |
1-hydroxy-5,5-dimethyl-2-phenylimidazolidine-4-thione |
CHEBI:190623 |
CCG-40717 |
FT-0607933 |
4-imidazolidinethione,1-hydroxy-5,5-dimethyl-2-phenyl- |
257869-91-3 |
AKOS022101915 |
STL323596 |
DTXSID50371434 |
W-206983 |
SR-01000212856-1 |
sr-01000212856 |
5,5-dimethyl-1-hydroxy-2-phenyl-imidazolidine-4-thionate |
CS-0336155 |
Drug Classes (1)
Class | Description |
benzenes | Any benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (5)
Assay ID | Title | Year | Journal | Article |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3
| High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6
| A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6
| A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | | | |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 13.13
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 13.13 (24.57) | Research Supply Index | 1.79 (2.92) | Research Growth Index | 4.92 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |